Enclomiphene side effects: what the trials actually found

Enclomiphene’s side-effect story is unusual for this space, because for once the comparison data is favorable rather than absent. In the randomized trials it was generally well tolerated, and where it has been tested directly against its older cousin clomiphene, it came out cleaner. But “well tolerated in a short trial” is not the same as “proven safe for years,” and the honest read has to hold both. For the full picture of how the drug works and what it’s for, start with the enclomiphene evidence monograph.

What the trials reported

Across the pooled SERM studies, a 2023 systematic review found no treatment-related unexpected safety findings, and concluded enclomiphene and clomiphene may be effective, reasonably safe alternatives to testosterone replacement — while explicitly calling for longer studies to clarify the safety profile.^[4] That is a measured endorsement, not a clean bill of health: the signal so far is reassuring, and the same authors say in the same breath that it is not yet complete.

Enclomiphene vs clomiphene: fewer adverse events

The most useful safety data is a 2024 retrospective comparison of enclomiphene against clomiphene in 66 men. Enclomiphene was associated with significantly lower odds of adverse events overall (odds ratio 0.18; 95% CI 0.07–0.44; P = 0.02).^[1] Broken down, the specific complaints men care about were each less frequent on enclomiphene: decreased libido(P = 0.001), reduced energy (P = 0.044), and mood changes(P = 0.03).^[1] Enclomiphene also produced a much smaller rise in estradiol than clomiphene (a change of −5.92 vs +17.50 pg/dL; P = 0.001) — relevant because estrogen-related side effects are part of why some men tolerate clomiphene poorly.^[1]

The hormone shifts are the mechanism, not a malfunction

Some of what changes on enclomiphene is the point of the drug, not a side effect. It deliberately raises LH and FSH — often above the normal range — and it raises estradiol, because more testosterone means more substrate for the enzyme that makes estrogen.^[2][3] These are expected, on-target effects of switching the hypothalamic-pituitary-gonadal axis back on. Whether a higher estradiol matters for a given man is a monitoring question, which is one reason clinicians track it. This is the same upstream-axis behavior we describe for enclomiphene versus TRT, where the gel does the opposite and suppresses these hormones.

What it did not disturb

Reassuringly, the detailed pharmacokinetic study found enclomiphene did not significantly affect thyroid hormone (TSH), ACTH, cortisol, lipids, or bone markers over the treatment period.^[2] The one unrelated marker that did move was IGF-1, which decreased— both enclomiphene and the comparison testosterone gel lowered it, with a somewhat greater reduction on enclomiphene.^[2] The clinical meaning of that IGF-1 dip over the long run is one of the open questions the literature has not answered.

What we still don’t know

The gaps are specific. We do not have long-term safety data on bone, heart or mortality for enclomiphene specifically.^[4] The short trials did not surface the visual disturbances sometimes raised with SERMs, but they were too small and brief to rule out rare events. And the entire favorable-tolerability case rests on a modest evidence base — one 66-man comparison and a handful of small RCTs — not the large, long, post-marketing record that testosterone therapy has accumulated. The right posture is cautious optimism with monitoring, not certainty.

The honest bottom line

On the evidence available, enclomiphene is generally well tolerated and appears to cause fewer side effects than clomiphene, with no effect on thyroid, cortisol, lipids or bone in the study that looked, and an expected rise in LH, FSH and estradiol that reflects the drug doing its job.^[1][2]The caveat is duration, not the data we have: nobody has the long-term safety picture, and the product is compounded. Anyone using it should be monitored — testosterone, LH, FSH, estradiol, and a hematocrit and lipid panel are reasonable — by a clinician, not self-directed from a forum. See also the dosage and enclomiphene vs clomid breakdowns.